| Date Filed | Type | Description |
| 09/01/2022 |
SEC STAFF ACTION
| Form SEC STAFF ACTION - SEC Staff Action: ORDER |
| 04/29/2020 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 04/03/2020 |
8-K
| Other Events |
| 03/31/2020 |
8-K
| Quarterly results |
| 03/11/2020 |
8-K
| Quarterly results |
| 02/14/2020 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 5% stake in Sophiris Bio Inc. |
| 12/23/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/23/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/23/2019 |
4
| HULME ALLISON (COO) has filed a Form 4 on SOPHIRIS BIO INC.|
Txns:
| Granted 123,000 options to buy
@ $0.36, valued at
$44.3k
|
|
| 12/23/2019 |
8-K
| Quarterly results |
| 12/13/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/13/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/09/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 11/12/2019 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 11/08/2019 |
10-Q
| Quarterly Report for the period ended September 30, 2019 |
| 11/07/2019 |
8-K
| Quarterly results |
| 10/22/2019 |
8-K
| Quarterly results |
| 10/08/2019 |
8-K/A
| Quarterly results |
| 09/12/2019 |
8-K
| Quarterly results |
| 09/06/2019 |
SC 13G
| ARMISTICE CAPITAL, LLC reports a 7.6% stake in Sophiris Bio Inc. |
| 09/06/2019 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 08/27/2019 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
| 08/27/2019 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/09/2019 |
10-Q
| Quarterly Report for the period ended June 30, 2019 |
| 08/09/2019 |
8-K
| Quarterly results|
Docs:
|
"Sophiris Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights SAN DIEGO and VANCOUVER, British Columbia, August 9, 2019 – Sophiris Bio Inc. , a biopharmaceutical company studying topsalysin , a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today reported financial results for the second quarter 2019 and recent corporate highlights. “During the second quarter of 2019, we received positive feedback from the EMA regarding the design of our Phase 3 clinical trial for localized prostate cancer which was a significant step forward in our development of topsalysin,” said Randall E. Woods, president and CEO of Sophiris. “We are now focused on our plan to fund this study and the Company going ..." |
|
| 06/28/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/28/2019 |
4
| HEPPELL JAMES L (Director) has filed a Form 4 on SOPHIRIS BIO INC.|
Txns:
| Granted 20,000 options to buy
@ $0.7782, valued at
$15.6k
|
|
| 06/28/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/28/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/28/2019 |
8-K
| Quarterly results |
| 06/07/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 05/09/2019 |
10-Q
| Quarterly Report for the period ended March 31, 2019 |
| 05/09/2019 |
8-K
| Quarterly results|
Docs:
|
"Sophiris Bio Reports First Quarter 2019 Financial Results SAN DIEGO and VANCOUVER, British Columbia, May 9, 2019 – Sophiris Bio Inc. , a biopharmaceutical company developing topsalysin , a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today reported financial results for the first quarter of 2019. “We continue to have dialog with the European Medicines Agency regarding the design for a potential Phase 3 clinical trial, which we developed with input from our scientific advisory board for the treatment of localized prostate cancer,” said Randall E. Woods, president and CEO of Sophiris. “We anticipate obtaining formal scientific advice from the EMA before the end of the second quarter and look forward to taking the ..." |
|
| 04/30/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
|